Lynx Announces Gene Expression Analysis Deal with AstraZeneca | GenomeWeb

NEW YORK, April 4  -Two weeks after penning a SNP collaboration with AstraZeneca, Lynx Therapeutics has agreed to perform gene expression assays for the Anglo-Swedish pharmaceutical giant using its MegaSort gene expression detection technology, Lynx said Wednesday.

Under the agreement, AstraZeneca will provide Lynx with tissue samples to analyze for differential gene expression patterns, and will make undisclosed milestone payments to Lynx. The parties did not disclose further terms of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.